Recent Finacing
Recent Raise
Arcus Biosciences is a clinical-stage oncology company developing antibodies and small molecules targeting the ATP–adenosine pathway (CD73, CD39, A2A), advancing multiple Phase 1–3 trials and internal combination programs.
